patent foramen ovale

Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Encyclopedia.

patent foramen ovale

PFO Cardiology An opening between the left and right atria which allows blood to bypass the lungs in utero; the FO normally closes shortly after birth, but remains open in up to 20%; a PFO is, in absence of other cardiac defects, is of no consequence

pa·tent for·a·men ova·le

(pa'tĕnt fōr-ā'mĕn ō-vā'lē)
Valvular incompetence of the patent foramen ovale of the heart; a condition contrasting with probe patency of the foramen ovale in that the valve of the foramen ovale has abnormal perforations in it, or is of insufficient size to afford adequate valvular action at the foramen ovale prenatally, or effect a complete closure postnatally.

patent foramen ovale

Persistence of the normal fetal opening in the internal wall of the heart (the FORAMEN OVALE) after birth.


1. open, unobstructed, or not closed.
2. apparent, evident.

patent ductus arteriosus (PDA)
abnormal persistence of an open lumen in the ductus arteriosus, between the aorta and the pulmonary artery, after birth. The ductus arteriosus is open during prenatal life, allowing most of the blood of the fetus to bypass the lungs, but normally this channel closes shortly before birth. When the ductus arteriosus remains open, it places special burdens on the left ventricle and causes a diminished blood flow in the aorta. May remain open for up to 5 days in foals. One of the most common congenital heart defects in dogs, but less common in cats. Causes a continuous 'machinery' murmur loud in systole, soft in diastole, and 'bounding' pulse.
patent ductus venosus
see ductus venosus.
patent foramen ovale
see foramen ovale (1).
patent medicine
a drug or remedy protected by a trademark, available without a prescription.
patent period
the period during a disease in which the causative agent can be detected by clinicopathological tests, e.g. for helminth eggs.
patent urachus
the urachus persists after birth and allows urine to drip out of the bladder through the umbilicus. See also urachus.
patent ventricular septum
includes several entities characterized by incomplete closure of ventricular wall. Characterized by palpable cardiac thrill and audible pansystolic murmur on both sides of the chest at birth, accompanied by exercise intolerance and developing dyspnea at rest.
References in periodicals archive ?
Right-to-left shunting after lobectomy through a patent foramen ovale.
Characteristics of patent foramen ovale associated with cryptogenic stroke: a biplane transesophageal echocardiographic study.
1) Hypoxemia is another serious consequence that may result from acute right-to-left shunting through a previously dormant atrial septal defect or patent foramen ovale.
Ironically, treatment of chronic migraine is an increasingly popular, albeit off-label, application for percutaneous closure of patent foramen ovale (PFO) and atrial septal defects (ASDs).
Transcranial Doppler studies indicate that up to half of patients who have migraine with aura have a patent foramen ovale (PFO).
Myxomas comprise nearly 50% of 311 histologically benign tumors, with only 18% occurring in the right atrium, We present a rare case of multiple right atrial myxomas in a patient with a patent foramen ovale presenting with multiple paradoxical emboli.
is an emerging medical device company that has developed the SeptRx[R] Intrapocket PFO Occluder (IPO), a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO).
Redwood City, CA) and Cook Medical (Bloomington, IN) entered into an agreement to develop and commercialize a specialized device designed to close the patent foramen ovale (PFO), a relatively common heart defect present in approximately 15 to 20 percent of the general population.
For years the exact relationship, if any, between migraine and patent foramen ovale was long on speculation and short on data.
Therapy for patent foramen ovale (PFO), found with increased frequency in the setting of stroke in the young, is controversial.
SeptRx, an emerging medical device company that has developed the SeptRx[R] Intrapocket PFO Occluder (IPO) -- a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO) -- reported today that it has completed enrollment of the first 20 patients in its ongoing "InterSEPT" (In-tunnel SeptRx European PFO Trial) clinical trial at Sankt Katharinen Hospital (Frankfurt, Germany) under principal investigator Horst E.